Currently submitted to: JMIR Preprints
Date Submitted: Jul 2, 2023
Open Peer Review Period: Jul 2, 2023 - Jun 16, 2024
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Null Hypothesis Proven in Sebum Infectant to Immune Reflex through Sebaceous Immunobiology by COVID-19 Vaccine
ABSTRACT
Background:
The on-going interventional trial was conceived from the phenomena of COVID-19 post-vaccination adverse events. The accumulated evidence has proven the null hypothesis with significant results that falsify the predominant belief in the vaccination method. The alternative hypothesis is adjusted with proton equilibrium and sebaceous immunobiology’s correlations with immune reflex.
Objective:
The research purposes to locate the infection path.
Methods:
The sole-participant interventional trial compared the main medicines in myocarditis treatment from Nifedipine to angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor-neprilysin inhibitor (ANRI) with increasing power level. T values and Z statistics are calculated for statistical analysis, and the introduction of proton-pump inhibitor is uncertain with the case’s neurodivergent conditions.
Results:
Inter-ACEI comparison suggests the introduction of beta blockers regulated the immune reflex through heart rate with the blood-borne pathogen. ANRI superiority suggests S2 pathogens can be more severe without S1 constraints, and raises alerts on SARS-CoV-2 mutational directions from Omicron. Historic data from the participant after the second COVID-19 vaccine shot recorded the viral entry through low-density lipoprotein cholesterol (LDL-C).
Conclusions:
The study protocol with data refers to SARS-CoV-2’s S2 infection concentration and viral characteristics in LDL-C in human host. It is highly probable that S2 pathogen starts with LDL-C in vaccine poisoning. It is possible that HDL-C levels are responsible for the cytokine storms in neurologically infected cases. The placebo effect is maximized by the vaccine mandates, and the mass psychological biases need time to be narrowed down. Clinical Trial: The study protocol is retrospectively registered on ClinicalTrials.gov with the identifier number NCT05711810.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.